Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 13, 2018 07:30 ET | Source: Moleculin Biotech, Inc.

Moleculin Biotech, Inc. Reports Financial Results for the Second Quarter Ended June 30, 2018

HOUSTON, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...
August 09, 2018 07:30 ET | Source: Moleculin Biotech, Inc.

Moleculin Seeks Approval from Polish Regulatory Agency for Skin Cancer Clinical Trial

HOUSTON, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...
July 31, 2018 07:30 ET | Source: Moleculin Biotech, Inc.

Moleculin Announces Enrollment Opens for Brain Tumor Trial of WP1066

HOUSTON, July 31, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...
July 18, 2018 07:30 ET | Source: Moleculin Biotech, Inc.

Moleculin Expects to Meet FDA IND Filing Requirements for its Pancreatic Cancer Drug Candidate with Development Work in Australia

HOUSTON, July 18, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. (Nasdaq:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...
July 11, 2018 07:30 ET | Source: Moleculin Biotech, Inc.

Moleculin Expands Operations to Australia; Taps R&D Incentive Program Capped at $20,000,000 AUD Turnover

HOUSTON, July 11, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...
June 26, 2018 07:30 ET | Source: Moleculin Biotech, Inc.

Moleculin Selected for the Russell Microcap Index

HOUSTON, June 26, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...
June 21, 2018 07:30 ET | Source: Moleculin Biotech, Inc.

Moleculin Announces $2.3 Million Registered Direct Offering Priced At-the-Market

HOUSTON, June 21, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of anti-cancer...
June 20, 2018 07:30 ET | Source: Moleculin Biotech, Inc.

Moleculin Receives Approval for Leukemia Clinical Trial

HOUSTON, June 20, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...
June 12, 2018 07:30 ET | Source: Moleculin Biotech, Inc.

Moleculin Targets accelerated FDA approval of WP1732; Pursues Development for Ocular Tumors

HOUSTON, June 12, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. (Nasdaq:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...
June 06, 2018 09:09 ET | Source: Moleculin Biotech, Inc.

Moleculin’s Breakthrough Discovery of a New Molecule for Cancer Treatment Advances to Development Agreement with the University of Iowa

HOUSTON, June 06, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right